The cyclical revival of psychedelics in psychiatric treatment
Current Medical Research and Opinion June 17, 2024 Francisco J Appiani, Stanley N Caroff 5 citations
Interest in psilocybin as a treatment for depression, especially treatment-resistant depression, has grown, but phase 2 studies have been inconclusive. Issues like maintaining double-blinding and the role of adjunctive psychotherapy introduce biases that complicate clear results. Historical patterns with psychoactive substances show an initial excess of optimism followed by addictive behaviors and public health risks. The efficacy and safety of psilocybin treatment have not been unequivocally established. Excessive optimism among researchers may lead to widespread adoption without sufficient evidence. A cautious, measured approach is needed to balance innovation and prudence in advancing depression treatments.